Biologic IgG level in primary immunodeficiency disease: The IgG level that protects against recurrent infection-Reference-Cited by-同舟云学术

Biologic IgG level in primary immunodeficiency disease: The IgG level that protects against recurrent infection

Published:2008-07 Issue:1 Volume:122 Page:210-212
ISSN:0091-6749
Container-title:Journal of Allergy and Clinical Immunology
language:en
Short-container-title:Journal of Allergy and Clinical Immunology

Author:

Bonagura Vincent R.,Marchlewski Robert,Cox Amanda,Rosenthal David W.

Publisher

Elsevier BV

Subject

Immunology,Immunology and Allergy

Reference7 articles.

1. Long term use of intravenous immune globulin in patients with primary immunodeficiency diseases: inadequacy of current dosage practices and approaches to the problem;Buckley;J Clin Immunol,1982

2. Early and prolonged intravenous immunoglobulin replacement therapy in childhood agammaglobulinemia: a retrospective survey of 31 patients;Quartier;J Pediatr,1999

3. Goals of therapy in antibody deficiency syndromes;Berger;J Allergy Clin Immunol,1999

4. Immunoglobulin therapy to control lung damage in patients with common variable immunodeficiency;de Gracia;Int Immunopharmacol,2004

5. National Government Services, Inc. Intravenous immune globulin (IVIG). LCD ID no. L699. Primary geographic jurisdiction: Connecticut, Delaware, New York; secondary geographic jurisdiction: Massachusetts. Available at: http://www.empiremedicare.com/nyorkpolicya/policy/l699_final.htm. Accessed March 18, 2008.

Cited by 147 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Neonatal bacteremia and sepsis;Remington and Klein's Infectious Diseases of the Fetus and Newborn Infant;2025

2. Mycoplasma pneumonia in a patient with X-linked agammaglobulinemia;BMC Infectious Diseases;2024-09-13

3. Infectious outcomes of a standardized subcutaneous immunoglobulin dose reduction strategy in primary immune deficiencies amid global shortage;2024-09-02

4. IgG testing, immunoglobulin replacement therapy, and infection outcomes in patients with CLL or NHL: real-world evidence;Blood Advances;2024-08-14

5. IgG replacement in multiple myeloma;Blood Cancer Journal;2024-07-25